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Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies with 
limited survival rate. Roles for peptidylarginine deiminases (PADs) have been studied in relation to a 
range of cancers with roles in epigenetic regulation (including histone modification and microRNA 
regulation), cancer invasion, and extracellular vesicle (EV) release. Hitherto though, knowledge on 
PADs in PDAC is limited. In the current study, two PDAC cell lines (Panc-1 and MiaPaCa-2) were 
treated with pan-PAD inhibitor Cl-amidine as well as PAD2, PAD3, and PAD4 isozyme-specific in-
hibitors. Effects were assessed on changes in EV signatures, including EV microRNA cargo (miR-21, 
miR-126, and miR-221), on changes in cellular protein expression relevant for pancreatic cancer pro-
gression and invasion (moesin), for mitochondrial housekeeping (prohibitin, PHB), and gene regula-
tion (deiminated histone H3, citH3). The two pancreatic cancer cell lines were found to predominantly 
express PAD2 and PAD3, which were furthermore expressed at higher levels in Panc-1, compared 
with MiaPaCa-2 cells. PAD2 isozyme-specific inhibitor had the strongest effects on reducing Panc-1 
cell invasion capability, which was accompanied by an increase in moesin expression, which in pan-
creatic cancer is found to be reduced and associated with pancreatic cancer aggressiveness. Some re-
duction, but not significant, was also found on PHB levels while effects on histone H3 deimination 
were variable. EV signatures were modulated in response to PAD inhibitor treatment, with the strong-
est effects observed for PAD2 inhibitor, followed by PAD3 inhibitor, showing significant reduction in 
pro-oncogenic EV microRNA cargo (miR-21, miR-221) and increase in anti-oncogenic microRNA 
cargo (miR-126). While PAD2 inhibitor, followed by PAD3 inhibitor, had most effects on reducing 
cancer cell invasion, elevating moesin expression, and modulating EV signatures, PAD4 inhibitor had 
negligible effects and pan-PAD inhibitor Cl-amidine was also less effective. Compared with MiaPaCa-
2 cells, stronger modulatory effects for the PAD inhibitors were observed in Panc-1 cells, which im-
portantly also showed strong response to PAD3 inhibitor, correlating with previous observations that 
Panc-1 cells display neuronal/stem-like properties. Our findings report novel PAD isozyme regulatory 
roles in PDAC, highlighting roles for PAD isozyme-specific treatment, depending on cancer type and 
cancer subtypes, including in PDAC. 
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pancreatic ductal adenocarcinoma (PDAC); moesin; prohibitin (PHB); deiminated histone H3 (citH3); 
microRNA (miR-21; miR-221; miR-126) 
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Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-associated 
deaths in Western countries and is the eighth main source of cancer-related deaths glob-
ally [1]. Despite advances in diagnostic technology, PDAC is usually diagnosed late and 
at an incurable stage, while early diagnosis is directly linked to improved survival [2]. 
Additionally, only a small portion of PDAC patients can benefit from chemotherapy and 
especially in advanced stages, the chemotherapeutics options are narrow with gemcita-
bine being the first drug treatment with improvement in the median survival only by a 
few weeks [3]. Moreover, while carbohydrate antigen 19-9 (CA 19-9) has been the most 
common diagnostic biomarker for PDAC in the last 30 years [4], it cannot be characterised 
as a specific biomarker, especially for asymptomatic patients [5]. Therefore, it is of great 
importance to identify novel molecular markers and pathways to aid biomarker discov-
ery, pancreatic cancer diagnostics, and for development of novel treatment options. 
Peptidylarginine deiminases (PADs) are a group of calcium-dependent enzymes that 
cause post-translational deimination/citrullination in target proteins, leading to changes 
in their structure and function, affecting protein–protein interactions, generation of neo-
epitopes, and modulating gene regulation [6–8]. This post-translational modification may 
also aid protein moonlighting, a phylogenetically conserved mechanism that allows pro-
teins to carry out numerous functions within one polypeptide chain, in relation to both 
physiological and pathophysiological functions [9,10]. PADs’ roles in numerous autoim-
mune and inflammatory conditions are well acknowledged, and in cancers PADs have 
been assessed for causing changes in epigenetic regulation, in relation to modulatory ef-
fects on EV communication as well as cancer invasion [11–17]. In mammals five isozyme-
specific PADs are described [6], which differ in their preference for protein targets and 
show tissue-specific expression. Therefore, a difference in prominence of the three main 
PAD isozymes (PAD2, 3, and 4) related to cancers is a topic of current interest, in relation 
to isozyme-specific targeting for specific cancer types, including heterogenous cancers as 
well as cancer subtypes [15,17]. Indeed, prominent roles for specific PAD isozymes have 
been associated with various cancers, including differences in modulating cell invasion 
proteins, effects on epigenetic regulation, and changes in EV signatures [11,12,15,17]. Cur-
rently, knowledge on PADs in PDAC is very limited and warrants further investigation. 
EVs are mediators of cell communication in physiological processes, but also in can-
cers, where they are key mediators for intra/inter-tumour communication by transferring 
proteins, enzymes, and nucleic acids (mRNA, miRNA, lncRNA, sncRNA) to surrounding 
cells as part of their cargo [17–20]. EVs are lipid bilayer-enclosed structures, with a diam-
eter of 30–1000 nm, and as they are released from their cells of origin they can be valid 
prognostic and diagnostic biomarkers. Due to EVs’ important roles in cancers, they are 
widely studied in a range of cancers, including also pancreatic cancer [21,22]. EVs released 
from cancer cells participate in the tumour’s intercellular communication, can influence 
the tumour microenvironment to promote angiogenesis, tumour growth, invasion and 
metastasis, as well as contribute to tumour metabolism [23–25]. Therefore, strategies to 
modulate EV signatures in cancer cells have been a focus of numerous studies, both with 
regard to limiting tumour growth in vivo, as well as sensitising cancer cells to chemother-
apy [12,13,15,26–33]. The effect of PADs on modulating EV signatures in cancer cells has 
been highlighted in a number of studies, assessing both pan-PAD inhibitor Cl-amidine as 
well as PAD2, PAD3, and PAD4 isozyme-specific inhibitors [11,12,15,17]. As this has 
shown effects on sensitising cancer cells to chemotherapy, alongside effects on pro- and 
anti-oncogenic microRNA EV cargo, novel interventions for targeting EV communication 
in pancreatic cancer may also be of considerable interest. 
microRNAs (miRs) are small (18 to 24 nucleotides long), endogenous, non-coding, 
evolutionary conserved, single-stranded RNA molecules, which can moderate gene ex-
pression at the post-transcriptional level through the binding to the complementary se-
quences of their target mRNAs at the 3′ untranslated regions (UTRs) [34]. More recent 
evidence has shown that the aberrant expression of miRs plays a significant role in 
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numerous human malignancies and is also associated with poor prognosis, invasion, me-
tastasis, and chemoresistance of PDAC [35]. Several signalling pathways associated with 
specific miRs are indeed related to PDAC progression. Specifically, upregulation of miR-
21 and downregulation of miR-126 have been considered to contribute to PDAC progres-
sion, through the post-transcriptional upregulation of KRAS [36]. It has been suggested 
that activated KRAS (G12D) stimulates the miR-21 promoter in human PDAC cells [37] 
and that miR-21 is involved in oncogenic RAS-induced cell proliferation [38]. Moreover, 
miR-21 indirectly targets KRAS, while downregulation of miR-126 directly regulates 
KRAS signalling pathway and controls KRAS protein translation [39]. Aberrant expres-
sion of miR-126 in PDAC is associated with HER2 overexpression [40,41], which is related 
to more than 30% of PDAC cases [42]. While the HER2/neu signalling pathway was found 
to be involved in PDAC progression, specific inhibition of Her2/neu pathway did, how-
ever, not affect the overall survival [43]. In breast cancer, upregulation in miR-21 is also 
linked to positive HER2 status, larger tumour size, higher tumour stage and grade, and 
poor patient survival [44]. Furthermore, miR-21 is involved in the MAPK signalling path-
way, which is important for the progression of pancreatic intraepithelial neoplasia (PanIN 
[45]). Overexpression of miR-21 has been shown to moderate cell proliferation and apop-
tosis of PDAC cells through the inhibition of both MAPK/ERK and PI3K/AKT signalling 
pathways [46]. Expression of miR-21 is also associated with the TGF-β signalling pathway, 
which is dysregulated in 80% of PDAC cases [47,48]. TGF-β is also associated with patho-
genesis of PDAC at later stages and inactivation of tumour suppressor genes, including 
SMAD4, which is involved in several biological processes such as cell proliferation, dif-
ferentiation, metastasis, and apoptosis [49,50]. miR-221 is one of the most dysregulated 
miRs in PDAC alongside miR-21 [51–53]. Upregulation of miR-221 has been found in a 
number of malignancies, including hepatocellular carcinoma, prostate adenocarcinoma, 
and colorectal carcinoma [54–57]. Moreover, a higher level of circulating miR-221 expres-
sion was detected in PDAC patients compared with patients with benign pancreatic tu-
mours or healthy controls [58]. Upregulation of miR-221 also plays a significant role in 
platelet-derived growth factor (PDGF)-mediated epithelial to mesenchymal transition 
(EMT) phenotype, migration, metastasis, and uncontrolled proliferation of PDAC cells 
[59]. Additionally, miR-221 promotes the proliferation of PDAC cells through PTEN-Akt 
signalling pathway [53]. Overexpression of miR-221 can result in uncontrolled prolifera-
tion of PDAC cells through the inhibition of both MAPK and TGF-β signalling pathways 
[60]. 
We have previously shown that both pan-PAD inhibitor Cl-amidine and PAD2, 3, 
and 4 isozyme-specific inhibitors modulate a range of pro- and anti-oncogenic miRs in 
cancers such as glioblastoma multiforme (GBM), as well as in cancer cell-derived EVs, 
including miR-21 and miR-126 [15,17]. Therefore it may be of great importance to identify 
whether such PAD-mediated effects may also affect miR expression and EV-mediated 
miR export in other types of cancers, including in PDAC. In previous studies, PAD inhib-
itors were furthermore found to affect cancer cell invasion proteins including moesin, 
which is a critical factor for cell migration and filopodia formation [61]. Interestingly, in 
pancreatic cancer, moesin was found to be strongly downregulated and this was associ-
ated with cancer aggressiveness [62], albeit other studies have reported that moesin con-
tributes to pathological state [63,64] and may be linked to metastasis [65]. PAD inhibitors 
were also found to modulate prohibitin (PHB), which is a multifaceted protein with key 
roles in mitochondrial housekeeping and tumourigenesis [66–68]. In pancreatic cancer, 
PHB was identified as a pro-tumour marker and negatively correlated with survival [69]. 
The assessment of proteins involved in cancer progression and invasion, as well as mito-
chondrial function, may be of considerable relevance, both with respect to PAD inhibitor-
mediated changes in total protein levels and with respect to their post-translational deimi-
nation, as this may affect protein structure, function, and protein–protein interactions 
[6,7]. Effects of PAD inhibitor treatment on histone H3 deimination has also been assessed 
in cancers, which may be of importance as post-translational modifications of histones, 
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including deimination, have been found to be players in cancers as well as in various in-
flammatory diseases and injury. For example, histone deimination was found to be re-
duced in response to Cl-amidine treatment in GBM [15] and reduced levels were also 
found in CNS injury following Cl-amidine treatment [70–72]. Histone citrullination is 
thought to mainly be modulated by PAD4, which has a classic nuclear localisation signal, 
although other PAD forms, including PAD2 and PAD3, were also found to localise to the 
nucleus and be able to deiminate histones, including H2A, H2B and H4 [13,14]. 
As current knowledge on PADs in PDAC is limited, this study aimed at assessing the 
effects of pan-PAD inhibitor Cl-amidine, as well as PAD2, PAD3, and PAD4 isozyme-
specific inhibitors on PDAC cell invasion, on moesin and prohibitin protein levels, as well 
as putative effects on histone H3 deimination in two PDAC cell lines. Furthermore, mod-
ulatory effects of the PAD inhibitors on EV signatures were assessed, including pro- and 
anti-oncogenic miR EV cargo. 
2. Results 
2.1. PAD Isozymes Are Differently Expressed in PDAC Cells 
Assessing PAD2, 3, and 4 isozyme-specific antibodies on protein extracts from Panc-
1 and MiaPaCa-2 cells showed bands at expected size for PAD2 and PAD3 (70–75 kDa 
size), while additional lower molecular weight bands were also observed. The PAD4 an-
tibody showed only a band at low molecular weight (25 kDa), while no reaction was seen 
in either cell line at an expected 70–75 kDa size for PAD4 (Figure 1A), or a similar pattern 
to the other two PAD isozyme-specific antibodies. Quantifying the protein expression 
against internal loading control (beta-actin) further showed that PAD2 and PAD3 were 
higher expressed in Panc-1 cells, compared with MiaPaCa-2 cells (2.6- and 2.4-fold for 
PAD2 and PAD3, respectively) (Figure 1B). 
 
Figure 1. Peptidylarginine deiminase (PAD) isozyme expression in Panc-1 and MiaPaCa-2 cells. (A) PAD2 and PAD3 
isoforms are detected at expected 70–75 kDa size range (arrows), although lower molecular weight bands are also ob-
served. PAD4 isoform does not show positive at the expected size of 75 kDa, only a band at 25 kDa is observed. (B) PAD2 
and PAD3 protein levels, normalised to internal beta-actin control, indicating that both isoforms are higher expressed in 
Panc-1 cells, compared with MiaPaCa-2 cells. 
2.2. Pan-PAD and PAD Isozyme-Specific Inhibitors Differently Modulate EV Release in 
Pancreatic Cancer Cells Following 1 h Treatment 
A considerable difference was observed on EV release profiles following treatment 
with pan-PAD inhibitor Cl-amidine, compared with the PAD isozyme-specific inhibitors. 
Cl-amidine somewhat (albeit non-significantly) increased total EV release in both cell lines 
at both concentrations tested (50 and 100 μm) and had varying effect on different EV 
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subpopulations, showing some reduction on EVs in the 0–100 nm size range (small EVs) 
in MiaPaCa-2 cells at 50 μm concentration (Figure 2). 
 
Figure 2. Pan-PAD inhibitor (Cl-amidine) treatment shows varying effects on the two pancreatic ductal adenocarcinoma 
(PDAC) cell lines under study with respect to cellular extracellular vesicle (EV) release. (A) Effects of Cl-amidine (50 μm 
1 h treatment) on EV release from Panc-1 cells. (B) Effects of Cl-amidine (100 μm 1 h treatment) on EV release from Panc-
1 cells. (C) Effects of Cl-amidine (50 μm 1 h treatment) on EV release from MiaPaCa-2 cells. (D) Effects of Cl-amidine (100 
μm 1 h treatment) on EV release from MiaPaCa-2 cells. For each set of histograms, Cl-amidine (50 or 100 μm)-treated and 
control (PBS)-treated cells were run under the same experimental conditions, respectively. Exact p-values are indicated (* 
highlights significance at p ≤ 0.05), error bars show SD; n = 3 biological replicates for all). 
When assessing the PAD isozyme-specific inhibitors, PAD2 inhibitor showed some 
reducing effects on total EV release in Panc-1 cells and on all sub-populations (albeit non-
significant) (Figure 3A), while the opposite was observed for MiaPaCa-2, with increased 
EV release, although this was also non-significant (Figure 3D). PAD3 inhibitor reduced 
EV release in Panc-1 cells, including all sub-populations (albeit non-significant) (Figure 
3B), but increased EV release somewhat (non-significant) from MiaPaCa-2 cells (Figure 
3E). PAD4 inhibitor had no effects on EV release from Panc-1 cells (Figure 3C), but in-
creased total EV release and small and medium-sized EV subpopulations, while it re-
duced release of larger EVs somewhat in MiaPaCa-2 cells (albeit all non-significant) (Fig-
ure 3F). Figure 4 shows representative nanoparticle tracking analysis (NTA) profiles for 
EV size distribution of EVs released from Panc-1 and MiaPaCa-2 control and PAD inhib-
itor treated cells (Figure 4A–L), alongside characterisation of EVs by Western blotting us-
ing the EV-specific markers CD63 and Flot-1 (Figure 4M). Morphology of EVs was verified 
by transmission electron microscopy (TEM) (Figure 4N). 




Figure 3. PAD2, PAD3, and PAD4 inhibitor treatments show PDAC cell line differing effects on cellular EV release. (A–C) 
Effects EV release from Panc-1 cells following 1 h treatment with: (A) PAD2 inhibitor, (B) PAD3 inhibitor, (C) PAD4 in-
hibitor. (D–F) Effects of PAD2 inhibitor on EV release from MiaPaCa-2 cells following 1 h treatment with: (D) PAD2 in-
hibitor, (E) PAD3 inhibitor, (F) PAD4 inhibitor. For each set of histograms, respectively, the PAD isozyme-specific inhibi-
tor-treated and control-treated cells were run under the same experimental conditions. Exact p-values are indicated (* 
highlights significance at p ≤ 0.05), error bars show SD; n = 3 biological replicates for all. 
 




Figure 4. Nanoparticle tracking analysis (NTA) size distribution profiles of EVs released from Panc-1 and MiaPaCa-2 cells 
following PAD inhibitor treatment for 1 h and EV characterisation by Western blotting (WB) and transmission electron 
microscopy (TEM). (A–D) Representative NTA profiles of Panc-1 cells following 1 h PAD inhibitor treatment: (A) Control 
DMSO-treated cells; (B) PAD2 inhibitor-treated cells; (C) PAD3 inhibitor-treated cells; (D) PAD4 inhibitor-treated cells; 
Representative NTA profiles of MiaPaCa-2 cells following 1 h PAD inhibitor treatment (E–H): (E) control DMSO-treated 
cells; (F) PAD2 inhibitor-treated cells; (G) PAD3 inhibitor-treated cells; (H) PAD4 inhibitor-treated cells. (I–L) show rep-
resentative NTA profiles of EVs released from pan-PAD inhibitor (Cl-amidine)-treated cells: (I) Control PBS-treated Panc-
1 cells; (J) Cl-am (100 μm)-treated Panc-1 cells; (K) Control PBS-treated MiaPaCa-2 cells; (L) Cl-am (100 μm)-treated Mi-
aPaCa-2 cells. (M) Western blotting analysis (WB) showing that EVs isolated from Panc-1 and MiaPaCa-2 cells are positive 
for the EV-specific markers CD63 and Flot-1. (N) Transmission electron microscopy (TEM) images showing characteristic 
EV morphology (arrows) for EVs isolated from PDAC cells under standard conditions; the scale bar represents 20 nm in 
all TEM images. In the NTA curves (A–L) the black line represents the mean of the five repetitive readings per individual 
sample and the red line represents standard error (+/−) between those same five readings per sample. Each treatment 
group was measured in three biological replicates. 
EV modal size was overall not significantly affected following 1 h PAD inhibitor 
treatment although in MiaPaCa-2 cells Cl-amidine significantly increased modal size fol-
lowing 50 μm treatment; this trend was also seen after 100 μm treatment for both Panc-1 
and MiaPaCa-2, although not significant. PAD2 inhibitor treatment had no effect on EV 
modal size of Panc-1 cells, but reduced modal size of EVs from MiaPaCa-2 cells somewhat 
(albeit non-significant). PAD3 inhibitor resulted in some increase in modal size of Panc-1-
derived EVs (albeit non-significant), while PAD4 inhibitor had no significant effects on 
EV modal size in either cell line (Figure 5, exact p-values are indicated). 




Figure 5. Modal EV size profiles from PDAC cells following 1 h treatment with pan-PAD and PAD isozyme-specific in-
hibitors. (A) Modal size of EVs released from Panc-1 cells following Cl-amidine treatment (50 and 100 μm respectively), 
compared with control (PBS)-treated cells (B) Modal size of EVs released from Panc-1 cells following PAD2 inhibitor treat-
ment, compared with control (DMSO)-treated cells. (C) Modal size of EVs released from Panc-1 cells following PAD3 and 
PAD4 inhibitor treatment, compared with control (DMSO)-treated cells. (D) Modal size of EVs released from MiaPaCa-2 
cells following Cl-amidine treatment (50 and 100 μm, respectively), compared with control (PBS)-treated cells. (E) Modal 
size of EVs released from MiaPaCa-2 cells following PAD2, PAD3, and PAD4 inhibitor treatment, compared with control 
(DMSO)-treated cells. The histograms show treatments run together, respectively. Exact p-values are indicated (* high-
lights significance at p ≤ 0.05), error bars show SD (n = 3 biological replicates for all). 
2.3. MicroRNA EV Cargo Is Differently Modulated in Response to 1 h PAD Inhibitor 
Treatments in PDAC Cells 
When assessing EV cargo for pro-cancerous-related miRs (miR-21, miR-221) respec-
tively, some significant expression changes were observed in response to the different 
PAD inhibitors (Figures 6 and 7). Pan-PAD inhibitor Cl-amidine (100 μm treatment for 1 
h) significantly reduced miR-21 in Panc-1 cells (Figure 6A), had no significant effects on 
miR221 EV cargo (Figure 6B), and reduced miR-126 somewhat (Figure 6C). In MiaPaCa-2 
cells, Cl-amidine did not have significant effects on levels of the different miRs assessed 
(Figure 6D–F), but did increase miR-126 somewhat, albeit not significantly. 




Figure 6. PAD inhibitor (Cl-amidine and isozyme-specific) mediated effects on EV microRNA 
cargo in PDAC cells. (A–C): Effects of Cl-amidine (1 h treatment at 100 μm) in Panc-1 cell-derived 
EVs on: (A) miR-21; (B) miR-221; (C) miR-126. (E–F): Effects of Cl-amidine on MiaPaCa-2 cell-de-
rived EVs (1 h treatment at 100 μm) for: (D) miR-21; (E) miR-221; (F) miR-126. Exact p-values are 
indicated (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001); error bars indicate SD. 
 
Figure 7. PAD isozyme-specific inhibitor (PAD2, PAD3, PAD4 inhibitor) mediated effects on EV miR cargo in PDAC cells. 
(A–C): Effects on Panc-1 cell-derived EVs for: (A) miR21; (B) miR221; (C) miR126. (E–F): Effects on MiaPaCa-2 cell-derived 
EVs for: (D) miR-21; (E) miR-221; (F) miR-126. Exact p-values are indicated (* p ≤ 0.05; *** p ≤ 0.001; **** p ≤ 0.0001); error 
bars indicate SD. 
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Following PAD isozyme-specific inhibitor treatment for 1 h, PAD2 and PAD3 inhib-
itors reduced both miR-21 and miR-221 significantly in Panc-1 cell-derived EVs, while 
PAD4 inhibitor had no significant effects (Figure 7A,B). miR-126 was elevated following 
PAD2 and PAD3 inhibitor treatment (significantly for PAD2 inhibitor), while PAD4 in-
hibitor had no effects (Figure 7C). In MiaPaCa-2 cells, none of the isozyme-specific inhib-
itors had significant effects on miR-21 cell-derived EV cargo, albeit some reduction as ob-
served with PAD2 inhibitor (Figure 7D) and significant reduction in miR-221 EV content 
was observed for PAD2 inhibitor. miR-126 was elevated in response to PAD2 inhibitor 
treatment (albeit not reaching statistical significance due to variation in the sample), while 
PAD3 and PAD4 inhibitors had no effect on miR-126 levels in MiaPaCa-2 cells (Figure 7F). 
2.4. PAD Inhibitors Differently Affect Moesin, PHB, and Deiminated Histone H3 Protein Levels 
in Panc-1 Cells, Following 1 h Treatment 
Following 1 h treatment with pan-PAD inhibitor (Cl-amidine) and the PAD2 iso-
zyme-specific inhibitor (AMF30a), respectively, the protein levels of moesin, PHB, and 
deiminated histone H3 (citH3) were assessed by Western blotting (Figure 8). In Panc-1 
cells, Cl-amidine did not affect moesin levels (Figure 8A), had some reducing (albeit non-
significant) effect on PHB levels (Figure 8B) and some reducing (albeit not significant) 
effect on citH3 levels (Figure 8A). In MiaPaCa-2 cells, moesin levels were increased fol-
lowing Cl-amidine treatment (albeit not reaching significance, p = 0.056) (Figure 9A), PHB 
protein levels were not significantly changed (Figure 9B), while citH3 levels were in-
creased (albeit non-significant) (Figure 9C). In addition, PAD2 inhibitor treatment changes 
in these proteins were further assessed in the Panc-1 cell line only, as PAD2 inhibitor 
showed most effects on EV signatures, and Panc-1 is considered the more aggressive 
PDAC cell line. In response to 1 h PAD2 inhibitor treatment, a strong significant increase 
was observed in moesin protein levels (Figure 10A), while no effect was observed on PHB 
levels (Figure 10B), and citH3 levels were somewhat (albeit not significantly) increased 
(Figure 10C). 
 
Figure 8. Changes in moesin, prohibitin, and deiminated histone H3 (citH3) protein levels in Panc-1 cells following 1 h Cl-
amidine treatment. The histograms show protein levels normalised against the internal loading control (β-actin) in treated 
versus control-treated cells as follows: (A) Moesin levels are not significantly changed; (B) Prohibitin (PHB) levels are 
slightly reduced following Cl-Am treatment; (C) citH3 levels are slightly reduced following Cl-Am treatment. Exact p-
values are shown (significance at p ≤ 0.05 was not reached), error bars show SD (n = 3 biological replicates for all, repre-
sentative Western blots are shown beneath the respective histograms). 




Figure 9. Changes in moesin, prohibitin, and citH3 protein levels in MiaPaCa-2 cells following 1 h Cl-amidine treatment. 
The histograms show protein levels normalised against the internal loading control (β-actin) in treated versus control-
treated cells as follows: (A) Moesin levels are increased (not reaching significance) following Cl-amidine treatment; (B) 
Prohibitin (PHB) levels are not significantly affected following Cl-Am treatment; (C) citH3 levels are increased (not reach-
ing significance) following Cl-Am treatment. Exact p-values are shown (significance at p ≤ 0.05, which was not reached), 
error bars show SD (n = 3 biological replicates for all, representative Western blots are shown beneath the respective his-
tograms). 
 
Figure 10. PAD2 inhibitor treatment (1 h) effects on moesin, prohibitin, and citH3 levels in Panc-1 cells. (A) PAD2 inhibitor 
treatment significantly increased Moesin levels in Panc-1 cells. (B) No significant effect was observed on PHB levels fol-
lowing 1 h PAD2 inhibitor treatment in Panc-1 cells. (C) Histone H3 deimination (citH3) was somewhat increased follow-
ing 1 h PAD2 inhibitor treatment, but not reaching significance. The error bars show SD, exact p-levels are shown (* high-
lights significance at p ≤ 0.05), and representative Western blots are shown for all protein assessments. The histograms are 
based on n = 3 per treatment. 
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2.5. PAD Isozyme-Specific Inhibitors Differently Affect Panc-1 Cell Invasion, Independent of 
Cell Proliferation 
The effect of pan-PAD inhibitor Cl-amidine and the isozyme-specific PAD2, PAD3, 
and PAD4 inhibitors, respectively, was assessed on the cell invasiveness of Panc-1 cells 
using Boyden chambers with Matrigel (Figure 11A). Panc-1 cells demonstrated noticeable 
invasion over 16 h (Figure 11A control), and incubation for 16 h with PAD2 and PAD3 
inhibitors resulted in the most significant suppression of invasiveness by 42.7% for PAD2 
inhibitor (p = 0.005) and 22.6% reduction for PAD3 inhibitor (p = 0.0005), respectively, 
while less effect was observed following treatment with Cl-amidine (23.3% reduction; p = 
0.0006), and least effect was seen following treatment with the PAD4 inhibitor (9.8% re-
duction; p = 0.029) (Figure 11A; n = 3 per treatment; see histograms for quantitative assess-
ment and representative figures of the cell invasion experiments). It must be noted, 
though, that PAD4 inhibitor did show some effects on cell invasiveness and therefore, 
while by Western blotting PAD4 was not detected at the correct molecular size, the ex-
pression and function of PAD4 in PDAC cells requires further investigation. Cell prolifer-
ation was also assessed for Panc-1 cells, following 16 h treatment with the different PAD 
inhibitors and showed negligible, confirming that the inhibitors did not affect prolifera-
tion. Cl-amidine treatment resulted in 5.8% reduction in cell proliferation, PAD2 inhibitor 
in 4.1% reduction in cell proliferation, PAD3 inhibitor in 3.1% reduction in cell prolifera-
tion, and PAD4 inhibitor in 3.1% reduction in cell proliferation (Figure 11B; see histograms 
for quantitative assessment and representative figures of the cell invasion experiments). 
Cell proliferation was also assessed for both cell lines for all PAD inhibitors used for a 1 h 
period, confirming no marked changes in cell proliferation for the concentrations used in 
either cell line (Figure 12). 
 





Figure 11. Cell invasion is differently affected by Cl-amidine and PAD2, 3, 4 isozyme-specific inhibitors in Panc-1 cells. 
(A) Cell invasion: Representative images (taken at 10× magnification) for cell invasion of Panc-1 cells following 16 h treat-
ment with Cl-amidine and the three PAD isozyme-specific inhibitors, compared to control (PBS or DMSO) treated cells 
are shown; cells are stained with crystal violet. (A1). The corresponding histogram for the MTT assay for Panc-1 cells, 
following the 16 h experiment in the presence of Cl-amidine and the three PAD isozyme-specific inhibitors, compared 
with control, respectively. (B) Cell proliferation: Representative images (taken at 10× magnification) for cell proliferation 
of Panc-1 cells following 16 h treatment with Cl-amidine and the three PAD isozyme-specific inhibitors, compared to 
control (PBS or DMSO) treated cells; cells are stained with crystal violet. (B1). The corresponding histogram for Panc-1 cell 
proliferation following 16 h treatment with Cl-amidine and the three PAD isozyme-specific inhibitors. Exact p-values are 
indicated (statistically significant differences are highlighted as * p < 0.05; ** p < 0.01 and *** p < 0.001).) and error bars 
show SD (n = 3 biological and 3 technical replicates for all). 
 
Figure 12. Cellular proliferation following Cl-amidine and/or PAD2, 3, 4 isozyme-specific inhibitor treatment in Panc-1 
and MiaPaCa-2 cells. MTT assay showing cell proliferation after 1 h treatment with Cl-Am (50 and 100 μm) shows little 
effect on either Panc-1 (A) or MiaPaCa-2 cells (C), albeit in some cases statistical significance is reached. Similarly, PAD2 
(5 μm), PAD3 (10 μm), and PAD4 (10 μm) inhibitors did not show marked changes on cell proliferation in Panc-1 cells (B) 
or MiaPaCa-2 cells (D) following 1 h treatment. Exact p-values are indicated (* p ≤ 0.05; ** p ≤ 0.01). 




This study assessed roles for PADs and PAD regulatory effects in two PDAC cell 
lines. Roles for PADs have previously been studied in relation to a range of cancers, with 
respect to epigenetic regulation, cancer invasion, and EV release. Hitherto though, 
knowledge on PADs in PDAC is limited. 
We established that PAD2 followed by PAD3 were the dominant isoforms in the 
PDAC cell lines under study (Panc-1 and MiaPaCa-2), while PAD4 protein was not de-
tected at the expected molecular size using Western blotting. This was further reflected in 
effects of PAD isozyme-specific inhibitors on PDAC cell invasion, showing the highest 
effects for PAD2 inhibitor, followed by PAD3 inhibitor, while PAD4 inhibitor was far less 
effective, compared with the other PAD inhibitors. It must be noted, though, that some 
effects were observed of PAD4 inhibitor, and while PAD4 was not detected at the expected 
molecular weight band in these cell lines, the expression and roles for PAD4 in PDAC will 
require further investigation. Pan-PAD inhibitor Cl-amidine, which has specificity against 
PAD1, PAD3, and PAD4 [73,74], also showed less effects compared with the PAD2-spe-
cific inhibitor. While some variability was observed in cell proliferation following treat-
ment with the different PAD inhibitors, comparing 1 and 16 h treatment times, this was 
below 6% in all cases. 
This is the first study to assess the three different PAD isozymes in PDAC, while 
previous studies have indeed pointed to roles for citrullination/deimination in PDAC, in-
cluding via deimination of specific target proteins (ENO1, HSP60, KRT8, and TUBB) [75]. 
Roles for neutrophil extracellular trap formation (NETosis) have also been implied [76], 
which can be partly PAD-driven and NETosis is commonly assessed using citH3 staining. 
Furthermore, using mouse models of PDAC, it was reported that circulating tumour-de-
rived EVs and citH3 levels are elevated [77]. In addition, tumour-infiltrating NETs, as as-
sessed by citH3 staining, were also shown to predict poor postsurgical survival of patients 
with PDAC [78]. Previously, deiminated α-enolase was identified as a target for anti-can-
cer immunity, including in PDAC murine models [79]. Interestingly, a patient diagnosed 
with fatal metastatic pancreatic cancer showed anti-cyclic citrullinated peptide antibodies 
that were linked to cancer polyarthritis [80]. It was also hypothesised that the deiminating 
activity of PAD and PAD homologues (ADI) in oral bacteria can contribute to pancreatic 
cancer [81]. 
Due to roles for EVs in cancer progression and previous observations for PAD inhib-
itor modulating effects on EV biogenesis and EV cargo, we assessed effects of PAD iso-
zyme-inhibitor treatment on changes in EV signatures in Panc-1 and MiaPaCa-2 cell lines, 
including pro- and anti-oncogenic EV miR cargo (miR-21, miR221, and miR-126). We 
found that EV signatures were differently modulated in response to the PAD isozyme-
specific inhibitors, including some effects observed on EV subpopulations and EV miR 
cargo. Overall, the strongest effects observed on EV signature modulation were for PAD2 
inhibitor in Panc-1 cells, followed by PAD3 inhibitor. These PAD inhibitors reduced pro-
oncogenic miR-21 and miR-221 EV cargo and elevated anti-oncogenic miR-126. The effects 
of PAD inhibitors on miR signatures is of considerable interest as several signalling path-
ways are associated with miRs in PDAC progression [82], including for the three miRs 
under study here. 
miR-21 is one of the main onco-miRs in a range of cancers, and its overexpression is 
associated with an elevated proliferation and invasion of PDAC cells [83]. Upregulation 
of miR-21 and downregulation of miR-126 are considered to contribute to PDAC progres-
sion through post-transcriptional upregulation of KRAS [36]. It has been suggested that 
miR-21 is involved in oncogenic RAS-induced cell proliferation [38] and indirectly targets 
KRAS, while downregulation of miR-126 directly targets KRAS signalling pathway and 
controls KRAS protein translation [39]. Also, upregulation of miR-21 targets PTEN, which 
further suppresses PI3K-AKT-mTOR signalling pathway, and this can lead to inhibition 
of cell cycle arrest, apoptosis, and gemcitabine sensitivity [84]. 
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miR-221 plays a significant role in platelet-derived growth factor (PDGF)-mediated 
EMT phenotype, migration, metastasis, and uncontrolled proliferation of PDAC cells [59]. 
An additional target gene, which is associated with miR-221 expression levels, is CDKN1B 
[85], which inhibits cell cycle through the modulation of cell proliferation, cell motility, 
and apoptosis [86]. Specifically, the overexpression of miR-221 can lead to the loss of ex-
pression of CDKNs, which are associated with unfavourable prognosis of PDAC [87]. 
miR-126, contrary to miR-21 and miR-221, can act as a tumour suppressor in several 
carcinomas such as lung, gastric, breast and PDAC through the inhibition of epidermal 
growth-factor-like domain 7 (EGFL7), Crk, and SLC7A5 [88]. Furthermore, altered expres-
sion of this miR can have as a consequence cellular migration and invasion through the 
inhibition of ADAM metallopeptidase domain 9 (ADAM9) target gene, which is com-
monly expressed in PDAC [89]. Aberrant expression of miR-126 in PDAC is associated 
with HER2 overexpression [40,41], which is related to more than 30% of PDAC cases [42], 
while direct correlation to survival rate has not been established [43] and the literature 
still remains controversial. Overall, the increase in the anti-oncogenic miR observed here 
in response to PAD inhibitor treatment points to anti-cancerous roles of PAD inhibitor 
application in PDAC. 
We furthermore assessed effects of the PAD inhibitors on changes in histone H3 
deimination (citH3), as well as in proteins relating to cell invasion (moesin) and mitochon-
drial housekeeping (PHB), all of which we have previously identified to be modulated by 
PAD inhibitor treatment in GBM cells [15,17]. As all three proteins are also involved in 
pancreatic cancer, alongside other cancers, changes in their cellular protein levels were 
assessed following pan-PAD inhibitor and PAD isozyme-specific inhibitor treatment. Fur-
thermore, as Panc-1 cells showed higher levels of PAD protein than MiaPaCa-2, they were 
used to assess cell invasion capability in the presence of the pan-PAD (Cl-amidine) and 
the PAD2, 3, and 4 isozyme-specific inhibitors. The PAD2-specific inhibitor displayed the 
strongest effects on reducing Panc-1 cell invasion capability, which was accompanied by 
an increase in moesin expression. This effect on moesin levels may be protective in PDAC, 
as a previous study identified that moesin expression is low in pancreatic cancer, includ-
ing PDAC, and that moesin knock-down increased migration, invasion, and metastasis 
[62]. Furthermore, some reduction, albeit not significant, was found in PHB levels follow-
ing Cl-amidine treatment in Panc-1 cells, but not with the other inhibitors, and was also 
identified in GBM following PAD inhibitor treatment [15,17]. Previous studies have iden-
tified PHB to be elevated in PDAC, to negatively correlate with survival, and furthermore, 
siRNA of PHB resulted in decreased cell invasion [69]. PHB also plays important roles in 
ERK-driven pancreatic tumorigenesis [90]. Effects on citH3 were also assessed as histone 
deimination has been associated to a range of cancers, both for epigenetic regulation as 
well as in relation to NETosis, including pancreatic cancer and associated venous throm-
bosis [76]. Results for citH3 protein levels varied, with some reduction (but not significant) 
in Panc-1 cells following Cl-amidine treatment, while citH3 was elevated in MiaPaCa-2 
cells. Also, following PAD2 inhibitor treatment, citH3 was elevated in Panc-1 cells. In ad-
dition to PAD4, both PAD2 and PAD3 have been localised and detected in the nucleus in 
spite of lacking a classic nuclear translocation site such as is found in PAD4 [70,91,92]. In 
cancer cells, PAD2, which is the most widely expressed isozyme in the body [93], was 
shown to deiminate histone H3 and play a role in gene regulation [91,94–96]. As PAD4 
has been considered the main responsible isoform for citH3 generation, this warrants fur-
ther investigation. Also, the difference observed between the two cell lines may be of some 
interest, showing cancer sub-type differences in response to the different PAD inhibitors. 
Previously, some reduced levels of citH3 were found in GBM following Cl-amidine treat-
ment [15]. While our current study provides some pilot insights into putative roles for 
PAD inhibitors modulating citH3 in PDAC, it will be of great interest to further assess 
changes in citH3 in additional PDAC cell lines, by both Western blotting and immunocy-
tochemistry, following treatment with the different PAD inhibitors. 
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The effect on elevated moesin levels following PAD2 inhibitor treatment observed 
here may be of some interest. Moesin is an ezrin-radixin-moesin (ERM) family member 
and involved in the regulation of cell adhesion, polarity, and migration [97]. Moesin has 
been associated with formation of filopodia, which are dynamic actin-rich membrane pro-
trusions important for cell adhesion, membrane trafficking (including EV internalisation) 
[61], and therefore also of importance in cancer cell adhesion and invasion [98–100]. In-
creased moesin expression was related to metastasis and to advanced clinical stage in ER-
positive breast cancer [101], while in higher grade GBM, moesin overexpression is also 
related to increased stem cell neurosphere formation [102,103]. In pancreatic cancer there 
are some contradictory findings regarding moesin expression. Studies have reported that 
moesin affects the progression of PC by activating MMP-7 and further promoting the re-
lease of TNF-α and IL-6 and decreasing the level of IL-10. The expression of moesin in PC 
tissues has close relations with the pathological stage of the disease, nerve infiltration, 
tumour location, and pain severity [64]. It was also reported, though, that moesin expres-
sion is reduced in PDAC and this is associated with pancreatic cancer aggressiveness, 
showing that moesin knock-down increased migration, invasion, and metastasis of pan-
creatic cancer and, furthermore, influenced pancreatic cancer extracellular matrix organi-
sation [62]. Moreover, moesin-dependent cytoskeleton remodelling is associated with an 
anaplastic phenotype of pancreatic cancer [62]. Based on these findings, increasing moesin 
expression should be anti-oncogenic in pancreatic cancer, and would align with elevated 
moesin protein levels observed particularly with PAD2 inhibitor treatment in Panc-1 cells 
in the current study. In previous studies moesin was found to be reduced in response to 
PAD inhibitor treatment in GBM [17]. The roles of moesin may be cancer type-specific or 
also differ in cancer subtypes, while deimination of moesin may also play roles, and this 
will require further investigation. 
While PAD2 inhibitor followed by PAD3 inhibitor had the most effects on reducing 
cancer cell invasion, elevating moesin expression, and modulating EV signatures in the 
PDAC cells in the current study, PAD4 inhibitor had negligible effects and pan-PAD in-
hibitor Cl-amidine was also less effective. This correlates with the differences observed in 
protein levels of the PAD isozymes in the cell lines and lack of positive signal for PAD4 at 
expected molecular size, also pointing to a negligible role for PAD4 in PDAC, while PAD2 
was the most prominent isozyme. Some differences were furthermore observed between 
the two PDAC cell lines under study, pointing to stronger effects of PAD inhibitors in 
Panc-1 cells, which, interestingly, also showed substantial response to PAD3 inhibitor, 
which may correlate with previous observations that this cell line contains neuronal-
like/stem-like properties [104]. 
Recent studies have indeed identified multifactorial roles for PAD2, PAD3, and 
PAD4 in cancer pathologies, depending on tumour type and cell lines [15,17,105–109]. 
PAD2 was found to play roles in gastric cancer and to have deleterious effects on tumour 
growth and metastasis in liver tumour cells [105]. Downregulation of PAD2 was on the 
other hand associated with colon cancer, while in normal colons PAD2 affects differenti-
ation and can suppress proliferation of colonic epithelial cells [107,108]. PAD inhibitor Cl-
amidine was shown to induce the upregulation of tumour suppressor miRs in colon can-
cer cells [110], as well as anti-oncogenic miR-126 in GBM [15]. Inhibition of PAD2 expres-
sion in breast cancer (MCF-7 cells) significantly decreased cell migration ability but did 
not affect cell proliferation and apoptosis [106], while use of Cl-amidine in MCF-7 cells 
reduced EV release and sensitised MCF-7cells to chemotherapy [12]. PAD4 also negatively 
regulates tumour invasiveness in breast cancer in vitro and in vivo models via citrullination 
of glycogen synthase kinase-3β (GSK3β) [109]. In GBM in vitro models, PAD2, 3, and 4 
isozyme expression was shown to differ between GBM cell lines [15], which correlated to 
different effectivity of the PAD isozyme-specific inhibitors on invasion properties and EV 
signature modulation [17]. Therefore it may be relevant to assess PAD isozyme-selective 
inhibitors for intervention with regard to tumour type, and cancer subtypes. Furthermore, 
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as we did not analyse effects of PAD inhibitors on apoptosis and potential alteration of 
the cell cycle in this study, this warrants further investigation. 
It may be of interest that, compared with MiaPaCa-2 cells, stronger modulatory ef-
fects for the PAD inhibitors were observed in Panc-1 cells, which importantly also showed 
strong response to PAD3 inhibitor. PAD3 has been associated with neuronal stem cell 
properties [92] and found, for example, to be elevated in specific GBM cell lines, which 
may therefore also have stronger stem-like properties as GBM are known for stem-ness 
[15,17]. Importantly, previous PDAC in vitro studies reported that Panc-1 cells display 
most neuronal/stem-like properties [104], which may cause it to reflect a more aggressive 
form and also highlight possible roles for PAD3 in such stem-like cancers. Therefore it will 
be of great interest to further investigate a link between PAD3 and cancer stem-ness in a 
wider range of cancers and cancer cell lines, including PDAC. In the context of cancer 
evolution, transmissible cancer types in the animal kingdom have been shown to display 
evolutionary conserved immune evasion pathways and, interestingly, also neuronal 
properties [111,112]. Therefore, it may be speculated that roles for PAD isozymes in cancer 
evolution are of some interest and of putative importance for wide ranging cancer type-
selective treatment. 
In summary, our findings identify novel roles for PADs in PDAC and furthermore 
highlight roles for the different PAD isozymes in different cancer types, as well as cancer 
subtypes, and the potential for PAD isozyme-specific treatment to promote anti-onco-
genic pathways in PDAC. 
4. Materials and Methods 
4.1. Pancreatic Cell Cultures and PAD Inhibitor Treatment 
Panc-1 (ATCC® CRL-1469™) and MiaPaCa-2 (ATCC® CRL-x1420™) PDAC cells 
were cultured according to the recommendations of ATCC, using 75 cm2 flasks and com-
plete Dulbecco’s Modified Eagle’s Medium (DMEM), with 10% foetal bovine serum (FBS) 
at 37 °C/5% CO2. The cells were split at 3–5 day intervals, depending on confluence. Cells 
were grown to 80% confluency in preparation for 1 h treatment with Cl-amidine (50 and 
100 μm; Cayman Chemical, Michigan, USA), PAD2 (AMF30a, 5 μm [113]), PAD3 (Cl4-
amidine, 10 μm [74]) and PAD4 (GSK199, 10 μm [114) inhibitors, respectively, based on 
cell viability tests (see Section 4.2) and also based on previously published literature using 
these inhibitors [12,15–17,74,113,114]. The PAD inhibitors were dissolved in 0.001% 
DMSO (except Cl-amidine, which was dissolved in PBS) and DMSO (0.001%) or PBS-
treated cells were used as controls, respectively. To assess effects on EV release, protein 
and miR expression, the cells were treated with the PAD inhibitors for 1 h, while cell pro-
liferation was assessed at 1 h and 16 h, and for the invasion assays the treatment time was 
16 h. For the isolation of Panc-1 and MiaPaCa-2 cell-derived EVs, the serum-containing 
medium was removed before application of the PAD inhibitors to avoid contamination of 
EVs from the FBS. Furthermore, before application of the medium containing the PAD 
inhibitors, the cells were washed in DPBS, and serum-free medium containing the respec-
tive PAD inhibitors were added for 1 h. DMSO or PBS was used as corresponding control 
treatment. Following 1 h incubation, the medium containing the EVs was removed from 
all treatment flasks, and the EVs were isolated as described in Section 4.4. For preparation 
of cell protein extracts for Western blotting (Section 4.7), the cells were trypsinised before 
further processing. 
4.2. Cell Viability Assays Following PAD Inhibitor Treatment 
The viability of Panc-1 and MiaPaCa-2 cells was assessed following 1 h incubation 
with pan-PAD inhibitor Cl-amidine (50 and 100 μm), PAD2 (AMF30a, 5 μm), PAD3 (Cl4-
amidine, 10 μm), and PAD4 (GSK199, 10 μm) isozyme-specific inhibitors, respectively, 
compared to PBS or DMSO control-treated cells. The procedure was similar to that previ-
ously described [17]. Cells were seeded at a density of 1 × 104 onto a 96-well plate (Nunc, 
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Denmark) for 2–3 days. Cells were treated with either medium containing only PBS or 
DMSO, compared with Cl-amidine, PAD2, PAD3, and PAD4 inhibitors, respectively (at 
the same concentrations as in Section 4.1), at 37 °C, 5% CO2 for 1 h. To determine the effect 
of the PAD inhibitors on cell proliferation, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) assay (Abcam, U.K.) was performed. A CLARIOstar plate reader 
(BMG Labtech, U.K.) was used to measure absorbance at 540–590 nm and normalised to 
the control. The experiments were performed in three biological and three technical re-
peats. Based on outcomes of this assay, further experiments (except initial EV modulation 
effects) involving Cl-amidine were carried out using Cl-amidine at 100 μm concentration. 
4.3. Modulation of EV Release Using Cl-Amidine, PAD2, PAD3, and PAD4 Isozyme-Specific 
Inhibitors Following 1 h Treatment 
The effect of Cl-amidine (50 and 100 μm), PAD2 (AMF30a; 5 μm), PAD3 (Cl4-ami-
dine; 10 μm), and PAD4 (GSK199; 10 μm) isozyme-specific inhibitors was assessed on EV 
release from Panc-1 and MiaPaCa-2 cells, following 1 h treatment according to previously 
described methods [17]. Panc-1 and MiaPaCa-2 cells were cultured and maintained in 
triplicates in T75 flasks, in the presence of pre-warmed culture medium (DMEM, supple-
mented with 10% FBS; Sigma-Aldrich, U.K.), according to the recommendations of ATCC. 
Both cell lines were grown to 80% confluency per T75 flask, whereafter the cells were split 
in culture medium (5 mL per T25 flask of pre-warmed DMEM, supplemented with 10% 
FBS; Sigma-Aldrich, U.K.). Each experiment was carried out when the cells in the flasks 
had reached 70–80% confluency. For EV isolation, treatment with Cl-amidine or the PAD 
isozyme-specific inhibitors and PBS or 0.001% DMSO, respectively, was carried out in bi-
ological triplicate per treatment as follows: Before PAD inhibitor application (or 
PBS/DMSO as controls), the serum-containing medium was removed from the T25 flasks, 
to avoid contamination of EVs from the FBS in the medium, and the cells were washed 
three times with pre-warmed Dulbecco’s PBS (DPBS). Then fresh pre-warmed serum- and 
EV-free DMEM, containing either the PAD inhibitors or control treatment (PBS, DMSO) 
(using 5 mL medium per T25 flask) were added for 1 h at 37 °C/5% CO2. Thereafter, the 
EV-containing media were collected, cell debris removed by centrifugation at 200× g for 
10 min and the EVs then isolated from the remaining supernatant (Section 4.4). 
4.4. EV Isolation and Quantification by Nanoparticle Tracking Analysis 
EV isolation was carried out according to previously established protocols [15,17] 
and according to the recommendations of the International Society of Extracellular Vesicle 
Research (ISEV) [115]. Differential centrifugation of the cell culture supernatants (5 mL 
collected from each flask) was carried out as follows: Supernatants were first centrifuged 
at 4000× g for 30 min at 4 °C for removal of cell debris, and the remaining supernatant 
ultracentrifuged for 1 h/4 °C at 100,000× g for EV enrichment. The supernatant was dis-
carded, the EV-enriched pellets resuspended in ice-cold DPBS, and the EVs ultracentri-
fuged again for 1 h/4 °C at 100,000× g. The final EV pellet was resuspended in 100 μL 
sterile DPBS. Nanoparticle tracking analysis (NTA) using the NS300 Nanosight (Malvern 
Panalytical Ltd., Malvern, U.K.) was carried out, using a 405 nm diode laser and a sCMOS 
camera, for EV quantification. For recording on the NTA, the samples were diluted 1:100 
in sterile-filtered EV-free DPBS, keeping the particle number per field of view at 30–50 
and the minimum concentration of samples at 5 × 107 particles/mL. The camera settings 
were according to the manufacturer’s instructions (Malvern Panalytical Ltd., Malvern, 
U.K.). Four 90 s videos were recorded per sample and averaged to obtain replicate histo-
grams. Each experiment was repeated in three biological replicates. 
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4.5. EV Characterisation by Transmission Electron Microscopy 
TEM was carried out according to previously described methods [15,17]. In brief, EVs 
from Panc-1 and MiaPaCa-2 cells were resuspended in 100 mM sodium cacodylate buffer 
(pH 7.4) and placed on a glow discharged grid with carbon support film. The grid was 
then placed in 2.5% glutaraldehyde in 100 mM sodium cacodylate buffer (pH 7.4), fol-
lowed by washing and staining with 2% aqueous Uranyl Acetate (Sigma-Aldrich). EVs 
were visualised using a JEOL JEM 1400 transmission electron microscope (JEOL, Japan), 
at a magnification of 30,000 to 60,000 and operated at 80 kV at a magnification of 30,000 to 
60,000. An AMT XR60 CCD camera (Deben, U.K.) was used for recording of digital im-
ages. 
4.6. Analysis of MicroRNAs miR-21, miR-126, and miR-221 in EV Cargo Following 1 h PAD 
Inhibitor Treatment 
MiR cargo was assessed in Panc-1 and MiaPaCa-2 cell-derived EVs, isolated from 
PAD inhibitor-treated and control-treated T25 flasks following 1 h incubation, as de-
scribed above and according to previously described methods [17]. The EVs were pro-
cessed for RNA isolation, followed by cDNA translation and assessment for the relative 
expression of miR-21, miR-126, and miR-221. RNA extraction was carried out using Trizol 
(Sigma, U.K.), while RNA concentration and purity were measured by NanoDrop Spec-
trophotometry at 260 nm and 280 nm absorbance. Reverse transcription of RNA to cDNA 
was carried out using the qScript microRNA cDNA Synthesis Kit (Quantabio, U.K.). The 
cDNA was used to assess expression of three selected microRNAs: miR-21, the main mi-
croRNA associated with pro-oncogenic function; miR-221, associated with cellular differ-
entiation; and miR-126, which is found protective in pancreatic cancer. U6-snRNA and 
hsa-let-7a-5p were used as reference RNA to normalise miR expression levels. The Per-
feCTa SYBR® Green SuperMix (Quantabio, U.K.) was used in conjunction with MystiCq 
microRNA qPCR primers for miR-21 (hsa-miR-21-5p), miR-126 (hsa-miR-126-5p), and 
miR-221 (hsa-miR-221-5p), which were all obtained from Sigma (U.K.). The sequences for 
U6-snRNA primers were U6 forward, 5′-GCTTCGGCAGCACATATACTAAAAT-3′ and 
hsa-let-7a-5p forward 5′-CCGAGCTGAGGTAGTAGGTTGTATA-3′ reverse 5′-
CGCTTCACGAATTTGCGTGTCAT-3′ for both. The conditions for thermocycling were: 
Denaturation at 95 °C/2 min, followed by 40 cycles at 95 °C/5 s and 60 °C/15 s, and exten-
sion at 72° C/15 s. The miR-21, miR-126, and miR-221 expression levels were normalised 
to that of U6 using the 2ΔΔCT method [116]. The experiments were carried out in three 
biological and three technical repeats. 
4.7. Western Blotting Analysis 
Total protein was extracted from treated and control-treated Panc-1 and MiaPaCa-2 
cells, using RIPA + buffer (Sigma, U.K.), supplemented with 10% protease inhibitor com-
plex (Sigma), pipetting gently at regular intervals while continuously shaking the cell 
preparation on ice for 2 h. Then the cell preparations were centrifuged at 16,000× g at 4 °C 
for 20 min to collect the supernatants containing the extracted proteins, which were re-
constituted in 2 x Laemmli sample buffer for Western blotting. In brief, protein samples 
in 2 x Laemmli sample buffer containing 5% β-mercaptoethanol were boiled for 5 min at 
100 °C, followed by SDS-PAGE analysis on 4–20% Mini-Protean TGX protein gels (Bio-
Rad, Watford, U.K.), and semi-dry Western blotting transfer. Ponceau S staining (Sigma) 
was used to assess even transfer to the nitrocellulose membranes (0.45 μm, BioRad). Block-
ing was carried out using 5% BSA (Sigma; in Tris buffered saline (TBS) containing 0.1% 
Tween20 (TBS-T)), for 1 h at room temperature (RT). Incubation with the primary anti-
bodies was carried out overnight at 4 °C (all diluted at 1/1000 in TBS-T) as follows: anti-
PAD2 (ab50257, Abcam), anti-PAD3 (ab50246), anti-PAD4 (ab50332), anti-prohibitin 
(ab75771), anti-moesin (ab52490), and anti-citH3 (ab5103). For EV characterisation, the 
EV-specific markers CD63 (ab68418; 1/1000 in TBS-T) and Flot-1 (ab41927; 1/2000 in TBS-
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T) were used. Washing was in TBS-T, followed by secondary antibody incubation with 
the corresponding HRP-conjugated anti-rabbit IgG (BioRad, U.K.) for 1 h at RT. Washing 
was in TBS-T and visualisation was carried out using enhanced chemiluminescence (ECL; 
Amersham, U.K.) together with the UVP BioDoc-ITTM System (Thermo Fisher Scientific, 
Hemel Hempstead, U.K.). For internal loading control and densitometry analysis of rela-
tive changes in protein expression of moesin, PHB, and citH3, the HRP-conjugated anti-
β-actin antibody (ab20272, Abcam, 1/5000 in TBS-T) was used and the blots analysed with 
ImageJ. 
4.8. Cancer Cell Invasion Assay 
The cell invasion assay was performed according to previous methods described in 
detail elsewhere [17,117]. Briefly, 5 × 105 cells (treated with pan-PAD inhibitor Cl-amidine 
and the PAD isozyme-specific inhibitors with respective PBS or DMSO control as before) 
were plated on Matrigel-coated transwell filters (Corning™ BioCoat™ Matrigel™ Inva-
sion Chamber with Corning™ Matrigel Matrix; BD Biosciences, Wokingham, UK) in a 
chemotactic gradient of 1:10% FBS. Following an incubation time of 16 h, the number of 
invaded cells was determined using the crystal violet assay (Abcam, U.K.) and the MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay (Abcam, U.K.). The 
same number of cells was plated and incubated in parallel for 16 h, for assessment of PAD 
inhibitor-mediated effects on cell proliferation. The CLARIOstar plate reader (BMG Lab-
tech, Aylesbury, UK) was used at 540–590 nm to measure absorbance and normalised ac-
cording to the control. The experiments were performed in three biological and three tech-
nical repeats. 
4.9. Statistical Analysis 
GraphPad Prism version 8 (GraphPad Software, San Diego, U.S.A.) was used for sta-
tistical analysis and preparation of graphs. One-way ANOVA was used together with 
Tukey’s post hoc analysis. Experiments were carried out in three biological replicates for 
EV analysis and Western blotting, and in three biological and three technical triplicates 
for microRNA analysis and cell invasion assays. The generation of NTA curves was per-
formed using the NanoSight 3.0 software (Malvern, U.K.), where the black lines in the 
curves represented the mean of the four repetitive 90 s readings, per individual sample 
(each treatment group was repeated in three biological replicates), and the red line repre-
sented the standard error (+/−). The histograms were presented as mean of data with the 
standard deviation (SD) indicated by the error bars. Significance was considered at p ≤ 
0.05. 
5. Conclusions 
This is the first study to assess PAD inhibitor treatment in PDAC cells. In the current 
study, two pancreatic cancer cell lines (Panc-1 and MiaPaCa-2) were treated with pan-
PAD inhibitor Cl-amidine alongside PAD2, PAD3, and PAD4 isozyme-specific inhibitors. 
PAD2 and PAD3 were found to be the dominating isoforms, and PAD inhibitor treatment 
affected EV signature profiles, including reducing pro-oncogenic miR-21 and miR-221, 
and increasing anti-oncogenic miR-126. PAD2 inhibitor, followed by PAD3 inhibitor, most 
effectively reduced Panc-1 cancer cell invasion and elevated moesin protein, relating to 
PDAC cell aggressiveness. Some reduction, but not significant, was also found in PHB 
levels while effects on histone H3 deimination were variable. Compared with MiaPaCa-2 
cells, stronger modulatory effects for the PAD inhibitors were observed in Panc-1 cells, 
which importantly also showed stronger response to PAD3 inhibitor; correlating with pre-
vious observations that Panc-1 cells display neuronal/stem-like properties. Our findings 
report novel PAD isozyme regulatory roles in PDAC, highlighting roles for PAD isozyme-
specific treatment, depending on cancer type and cancer subtypes, including in PDAC. 
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